BIRC5 and colorectal cancer: We have identified HLA-A24-restricted CTL epitope survivin-2B80-88 derived from survivin-2B previously and reported that it had a high potency of CTL induction in various cancer patients including breast cancer, colorectal cancer, and gastric cancer patients [23].